Dr. Jiang has more than 25 years of extensive pharma and biotech experience. Huiping began her pharmaceutical career at AstraZeneca prior to joining Boehringer Ingelheim heading Genomics and Genetics group before transitioning to Regulatory Affairs.

Prior to joining Valerio Therapeutics, she served as Senior Vice President/Head of Regulatory Affairs at Epizyme, Inc., and board member/Interim President at Qx Therapeutics.

Dr. Jiang brings to us drug development experience from early discovery to marketing authorization in both big pharma and small biotech settings. Most recently she led the regulatory submissions and approvals of 2 NDAs within six months for TAZVERIK which also included a successful ODAC and a preapproval inspection.

She received her B.S. in biochemistry from Nanjing University and her Ph.D. in cell and molecular biology from Clarkson University and conducted postdoctoral research at the California Institute of Technology.